Please wait while we load the requested 10-K report or click the link below:
https://last10k.com/sec-filings/report/1651431/000119312521098414/d18214d10k.htm
SEC Filings
CMPI Annual Reports
CMPI Quarterly Reports
CMPI Corporate News
Bylaw Change
Change in Assets
Change in Control
Event for Officers
Financial Exhibit
Listing Status
Security Holders Change May 2022
Earnings Release
Financial Exhibit May 2022
Financial Exhibit
New Agreement April 2022
Financial Exhibit
Other Events April 2022
Earnings Release
Financial Exhibit March 2022
Event for Officers March 2022
Event for Officers
Financial Exhibit February 2022
Event for Officers
Financial Exhibit February 2022
Event for Officers
Financial Exhibit December 2021
Financial Exhibit
Other Events
Regulated Disclosure December 2021
Bylaw Change
Change in Assets
Change in Control
Event for Officers
Financial Exhibit
Listing Status
Security Holders Change
Change in Assets
Change in Control
Event for Officers
Financial Exhibit
Listing Status
Security Holders Change
May 2022
Earnings Release
Financial Exhibit
Financial Exhibit
May 2022
Financial Exhibit
New Agreement
New Agreement
April 2022
Financial Exhibit
Other Events
Other Events
April 2022
Earnings Release
Financial Exhibit
Financial Exhibit
March 2022
Event for Officers
March 2022
Event for Officers
Financial Exhibit
Financial Exhibit
February 2022
Event for Officers
Financial Exhibit
Financial Exhibit
February 2022
Event for Officers
Financial Exhibit
Financial Exhibit
December 2021
Financial Exhibit
Other Events
Regulated Disclosure
Other Events
Regulated Disclosure
December 2021
CMPI Registration of Securities
Last10K.com | 10-K Annual Report Mon Mar 29 2021
Cover Page - USD ($) | 12 Months Ended | |
|---|---|---|
Dec. 31, 2020 | Mar. 29, 2021 | |
| Document Information [Line Items] | ||
| Document Type | 10-K | |
| Amendment Flag | false | |
| Document Period End Date | Dec. 31, 2020 | |
| Document Fiscal Year Focus | 2020 | |
| Document Fiscal Period Focus | FY | |
| Document Annual Report | true | |
| Document Transition Report | false | |
| Entity Interactive Data Current | Yes | |
| Entity Registrant Name | Checkmate Pharmaceuticals, Inc. | |
| Entity Central Index Key | 0001651431 | |
| Current Fiscal Year End Date | --12-31 | |
| Entity Current Reporting Status | Yes | |
| Entity Well-known Seasoned Issuer | No | |
| Entity Voluntary Filers | No | |
| Entity Shell Company | false | |
| Entity Filer Category | Non-accelerated Filer | |
| Entity Small Business | true | |
| Entity Emerging Growth Company | true | |
| Entity Ex Transition Period | false | |
| Entity Incorporation, State or Country Code | DE | |
| Entity Address, State or Province | DE | |
| Entity Address, Country | MA | |
| Title of 12(b) Security | Common Stock | |
| Trading Symbol | CMPI | |
| Security Exchange Name | NASDAQ | |
| Entity Public Float | $ 314,566,207 | |
| Entity Common Stock, Shares Outstanding | 21,618,395 | |
| ICFR Auditor Attestation Flag | false |
View differences made from one year to another to evaluate Checkmate Pharmaceuticals, Inc.'s financial trajectory
Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Checkmate Pharmaceuticals, Inc..
Assess how Checkmate Pharmaceuticals, Inc.'s management team is paid from their Annual Proxy
Checkmate Pharmaceuticals, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2021 10-K Annual Report includes:
- Voting Procedures
- Board Members
- Executive Team
- Salaries, Bonuses, Perks
- Peers / Competitors
SEC Filing Tools
Rating
Learn More
Filter Sentiment:
Filter Category:
Filter Subcategory:
-
Financial - Expense Highlight
These payments are comprised of a license fee of $1.0 million which was recognized in research and development expense in 2015, a $1.0 million milestone payment in connection with the dosing of the first patient in our first Phase 1 clinical trial, which was recognized in research and development expense in 2016, and a $0.3 million license amendment fee in connection with the signing of the second amendment to the Kuros License Agreement, which was recognized in research and development expense in 2018.
-
Legal - Other Highlight
We also anticipate that we will experience a significant increase in accounting, audit, legal, regulatory, compliance and director and officer insurance costs as well as investor and public relations expenses associated with operating as a public company.
-
Financial - Expense Highlight
We expect to continue to incur significant expenses and to increase operating losses for at least the next several years.
-
Financial - Cash Flow Highlight
We have incurred recurring losses and had negative operating cash flows since inception and our ability to generate product revenue sufficient to achieve profitability will depend heavily on the successful development and eventual commercialization of CMP-001 or any other products we acquire or develop.
-
Financial - Expense Highlight
We expect our expenses to increase substantially in connection with our ongoing activities, particularly as we advance the preclinical activities and clinical trials for CMP-001 and any other product candidates that we may develop or acquire in the future.
-
Financial - Expense
Milestone payments under license agreements...Read more
-
Financial - Expense
In addition, as we advance...Read more
-
Other - Other
We have elected to not...Read more
-
Revenue - Product
If we raise additional funds...Read more
-
Financial - Expense
As a result, we expect...Read more
-
Financial - Expense
Changes in accounts payable, accrued...Read more
-
Financial - Expense
We received approximately $67.7 million...Read more
-
Financial - Expense
As noted above, in August...Read more
-
Financial - Expense
Such amounts are expensed as...Read more
-
Other - Other
The financial terms of these...Read more
-
Other - Other
Change in Fair Value of...Read more
-
Financial - Expense
We recognize external development costs...Read more
-
Revenue - Product
We would cease to be...Read more
-
Financial - Expense
This process involves reviewing open...Read more
-
Financial - Expense
This process involves reviewing open...Read more
-
Other - Other
Other exemptions and reduced reporting...Read more
-
Revenue - Product
We believe that the net...Read more
-
Other - Other
We may be unable to...Read more
-
Financial - Expense
Additionally, if we believe a...Read more
-
Financial - Shares
In connection with the IPO,...Read more
-
Other - Other
Although we do not expect...Read more
-
Financial - Expense
There may be instances in...Read more
-
Financial - Expense
We anticipate that our general...Read more
-
Other - Other
In a clinical trial of...Read more
Financial Statements, Disclosures and Schedules
Inside this 10-K Annual Report
Cover Page
Consolidated Balance Sheets
Consolidated Balance Sheets (Parenthetical)
Consolidated Statements Of Cash Flows
Consolidated Statements Of Operations And Comprehensive Loss
Consolidated Statements Of Redeemable Convertible Preferred Stock And Stockholders' (Deficit)
Consolidated Statements Of Redeemable Convertible Preferred Stock And Stockholders' (Deficit) (Parenthetical)
Accrued Expenses
Accrued Expenses (Tables)
Accrued Expenses - Schedule Of Accrued Expenses (Detail)
Commitments And Contingencies
Commitments And Contingencies - Additional Information (Detail)
Common Stock
Convertible Notes
Convertible Notes - Additional Information (Detail)
Defined Contribution Plan
Defined Contribution Plan - Additional Information (Detail)
Fair Value Measurement
Fair Value Measurement (Tables)
Fair Value Measurement - Schedule Of Fair Value Assets And Liabilities Measured On Recurring Basis (Detail)
Income Taxes
Income Taxes (Tables)
Income Taxes - Additional Information (Detail)
Income Taxes - Schedule Of Components Of Company Deferred Tax Assets (Detail)
Income Taxes - Schedule Of Reconciliation Of U.S. Federal Statutory Income Tax Rate And Effective Income Tax Rate (Detail)
Income Taxes - Summary Of Unrecognized Benefits (Detail)
Investments
Investments (Tables)
Investments - Additional Information (Detail)
Investments - Summary Of Amortized Cost And Estimated Fair Value Company's&Amp;#160;Available For Sale&Amp;#160;Investments (Detail)
Investments - Summary Of Estimated Amortized Costs And Fair Value Of The Debt Securities Available For Sale And Held To Maturity (Detail)
Nature Of Business
Nature Of Business - Additional Information (Detail)
Net Loss Per Share Attributable To Common Stockholders
Net Loss Per Share Attributable To Common Stockholders (Tables)
Net Loss Per Share Attributable To Common Stockholders - Summary Of Potentially Dilutive Shares Excluded From The Calculation Of Diluted Net Loss (Detail)
Redeemable Convertible Preferred Stock
Redeemable Convertible Preferred Stock (Tables)
Redeemable Convertible Preferred Stock - Additional Information (Detail)
Redeemable Convertible Preferred Stock - Schedule Of Redeemable Convertible Preferred Stock (Detail)
Stock Based Compensation
Stock Based Compensation - (Tables)
Stock Based Compensation - Additional Information (Detail)
Stock Based Compensation - Schedule Of Fair Value Of Stock Option Awards On The Grant Date Using The Black-Scholes Option Valuation Model (Detail)
Stock Based Compensation - Summary Of Total Stock-Based Compensation Expense (Details)
Stock Based Compensation - Summary The Activity Under The Company's Stock Option Plan (Detail)
Subsequent Events
Subsequent Events - Additional Information (Detail)
Summary Of Significant Accounting Policies
Summary Of Significant Accounting Policies (Policies)
Summary Of Significant Accounting Policies -Additional Information (Detail)
Valuation Of Series B Preferred Stock Tranche Right Liability
Valuation Of Series B Preferred Stock Tranche Right Liability (Tables)
Valuation Of Series B Preferred Stock Tranche Right Liability - Additional Information (Detail)
Valuation Of Series B Preferred Stock Tranche Right Liability - Schedule Of Aggregate Fair Value Of The Company's Series B Preferred Stock Tranche Right Liability (Detail)
Valuation Of Series B Preferred Stock Tranche Right Liability - Schedule Of Fair Value, Liabilities Measured On Recurring Basis, Unobservable Input Reconciliation (Detail)
Material Contracts, Statements, Certifications & more
Checkmate Pharmaceuticals, Inc. provided additional information to their SEC Filing as exhibits
Exhibit 4.3: Instruments Defining The Rights Of Security Holders, Including Indentures
Exhibit 10.13: Material Contract
Exhibit 21.1: Subsidaries Of The Registrant
Exhibit 23.1: Consents Of Experts And Counsel
Exhibit 31.1: Rule 13A-14(A)/15D-14(A) Certification
Exhibit 31.2: Rule 13A-14(A)/15D-14(A) Certification
Exhibit 32.1: Section 1350 Certification
Ticker: CMPI
CIK: 1651431
Form Type: 10-K Annual Report
Accession Number: 0001193125-21-098414
Submitted to the SEC: Mon Mar 29 2021 4:52:25 PM EST
Accepted by the SEC: Mon Mar 29 2021
Period: Thursday, December 31, 2020
Industry: Biological Products No Disgnostic Substances
External Resources:
Stock Quote
Social Media
Bookmark the Permalink: https://last10k.com/sec-filings/cmpi/0001193125-21-098414.htm
SEC Filing Exhibit
PDF Download
Loading SEC Filing Exhibit...
Excel DownloadLoading SEC Filing Financial Summary...